Six readers
| reader | found | score |
|---|---|---|
| genetics Open Targets | no genetic evidence; overall 0.00 from other evidence | 0.00 |
| cell type Human Protein Atlas | expressed broadly, no clear home in brain cells | 0.40 |
| chemistry Open Targets | compounds already reach it: citatuzumab bogatox, zolimomab aritox, elx-02 +2 | 1.00 |
| trials ClinicalTrials.gov | no Parkinson's trials on record: an open field | 1.00 |
| literature PubMed | no papers tie it to Parkinson's yet | 1.00 |
| pathways Reactome | 16 pathways; mostly other | 0.30 |
No case: the score is under the bar. Receipt 15963
Sealed predictions
- RPL12 in dopamine neurons, braak-0.15 (p 0.697) → +0.06 (p 0.877)receipt 15970
Swarm cases
receipt 15970: RPL12 in dopamine neurons, braak
- power
- full sample -0.05 (p 0.847, n 18), 95% CI -0.50 to +0.43. the interval is wide: not enough donors to tell.
- confounder
- adjusted for sex: -0.02 (p 0.928, n 18). does not hold up.
- composition
- dopamine neurons share of nuclei vs axis +0.05 (p 0.854); controlling for it: +0.11 (p 0.677, n 18). could be the mix.
- skeptic
- leave-one-out range -0.17 to +0.07, sign flips 4; without severely affected donors -0.05 (p 0.847, n 18). fragile.
- cell type
- no other cell group does better.
- axis
- no measure beats "tracks Braak Lewy-body stage" for RPL12 in dopamine neurons.
case closed: nothing better to follow up.
Receipts
loading the receipts